|
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
|
Ongoing
|
Sorafenib (Nexavar)
|
3
|
RTOG 1112
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
|
Ongoing
|
DOCETAXEL, Paclitaxel, TAMOXIFEN and Letrozole
|
3
|
S1007
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
|
Ongoing
|
Ozanimod HCl
|
3
|
RPC01-3203
|
King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh)
|
|
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
|
Ongoing
|
CISPLATIN (CISPLATYL )
|
2
|
NRG-HN002
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
Study of Aflibercept in Uveitic Macular EDema (SAUD study)
|
Rejected
|
Aflibercept
|
3
|
18176/
|
King Khaled Eye Specialist Hospital (Riyadh)
|
|
A Phase Ib study to determine the safety and immunogenicity of the candidate Middle East Res-piratory Syndrome Coronavirus (MERS-CoV) vaccine ChAdOx1 MERS in healthy adult Middle Eastern volunteers
|
Ongoing
|
vaccine ChAdOx1 MERS
|
1
|
CT18/004/R
|
King Abdulaziz Medical City NG (Riyadh)
|
|
Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia
|
Rejected
|
Dasatinib
|
2
|
LPI-JOR-LEB-KSA-TUN-
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease.
|
Ongoing
|
Ozanimod HCl
|
3
|
RPC01-3201
|
King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh)
|
|
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease
|
Ongoing
|
Ozanimod HCl
|
3
|
RPC01-3204
|
King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh)
|
|
A multi-center open-label parallel group randomized controlled trial to compareiGlarLixi versus premixed insulin in patients with type 2 diabetes who have failedto achieve glycemic control with basal insulin and oral antidiabetic agents
|
Ongoing
|
Insulin glargine/Lixisenatide
|
3b
|
LPS15017
|
King Fahad Medical City (Riyadh)
|
